21
Views
4
CrossRef citations to date
0
Altmetric
Original Article

A pilot study of buprenorphine – naloxone combination tablet (Suboxone®) in treatment of opioid dependence

, , &
Pages 311-317 | Received 15 Mar 2004, Accepted 18 May 2004, Published online: 12 Jul 2009

References

  • Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Compar- ison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151: 1025–30.
  • Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2003;2:CD002207.
  • Chiang CN, Hawks RL. Pharmacokinetics of the combina- tion tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003;70(Suppl.): S39– 47.
  • Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations; why the 4:1 ratio for treatment? Drug Alcohol Depend 2003;70(Suppl.): S29– 37.
  • Darke S, Ross J, Hall W. The injection of methadone syrup in Sydney, Australia. Technical Report no 23. Sydney: National Drug and Alcohol Research Centre, 1995.
  • Darke S, Topp L, Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996 – 2000: 5-year monitoring of trends from the Illicit Drug Reporting System. Drug Alcohol Rev 2002; 21: 27–32.
  • Sunjic S, Zador DA. Methadone related deaths in New South Wales, July 1990 – December 1995. Drug Alcohol Rev 1999; 18: 409–16.
  • Breen C, Degenhardt L, Roxburgh A et al. Australian Drug Trends 2002: findings of the Illicit Drug Reporting System. NDARC Monograph no. 50. Sydney: National Drug and Alcohol Research Centre, 2003.
  • Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti J-P. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96: 267–72.
  • Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569–80.
  • Auriacombe M, Franques P, Tignol J. Deaths attributable to buprenorphine vs methadone in France. JAMA 2001; 285: 45 – 6.
  • Fudala P, Bridge PT, Herbert S et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine-naloxone. N Engl J Med 2003; 349: 949–58.
  • Barau K, Thirion X, Micallef J, Chuniaud-Louche C, Bellemin B, San Marco J. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 2001; 96: 1433–41.
  • Mattick RP and the NEPOD study Group. National evaluation of pharmacotherapies for opioid dependence: report of results and recommendations. Sydney: National Drug and Alcohol Research Centre, 2001.
  • Milby JB. Methadone maintenance to abstinence: how many make it? J Nerv Ment Dis 1988;176;409 – 22.
  • Ball JC, Ross A. The effectiveness of methadone main- tenance treatment: patients, programs, services and out- come. New York: Springer-Verlag, 1991.
  • Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost- effectiveness analysis. Drug Alcohol Depend 2003; 71: 295–302.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.